5637 Orthotopic Mouse Model Service for Bladder Cancer

The 5637 orthotopic mouse model for bladder cancer offers a representative basal-subtype preclinical system that recapitulates the intermediate-grade transitional cell carcinoma microenvironment, including stromal interactions and epithelial plasticity relevant to non-muscle invasive disease progression. Alfa Cytology provides this specialized orthotopic model service with integrated capabilities spanning cell line authentication, surgical implantation, longitudinal tumor monitoring, and multi-omic endpoint characterization—enabling researchers to generate actionable preclinical data for bladder cancer therapeutic development.

Overview of 5637 Orthotopic Mouse Model for Bladder Cancer

The 5637 cell line was established in 1974 from a grade II transitional cell carcinoma of the urinary bladder and represents the basal molecular subtype of urothelial carcinoma. Unlike luminal-papillary models, 5637 exhibits high expression of basal cytokeratins (CK5/14), elevated EGFR signaling, and robust proliferative capacity, while showing minimal expression of urothelial differentiation markers such as FOXA1 and GATA3. Genetically, the line harbors a TP53 missense mutation (p.R280T), an ATM variant (p.H1876Q), and an activating ERBB2 alteration (p.S310F), placing it within the DNA-damage response and receptor-tyrosine kinase axis frequently dysregulated in intermediate-grade bladder tumors. In orthotopic settings, 5637 cells engraft within the bladder wall to form moderately differentiated epithelial neoplasms that retain cohesive nest-like architecture and display focal stromal reorganization, offering a faithful platform for studying basal-subtype tumor biology.

Fig 1. Gross photographs of 5637 and T24 mice with subcutaneous transplantation, array of dissected tumors, and bar chart of tumor weight. (Dai, Ranran, et al., 2021)

The 5637 orthotopic model occupies a unique position between well-differentiated luminal lines and highly aggressive mesenchymal subtypes, making it particularly valuable for evaluating therapies targeting DNA replication stress, checkpoint kinase inhibition, and epithelial-to-mesenchymal transition plasticity. Because the model preserves native bladder architecture—including exposure to urinary metabolites and mechanical wall tension—it enables pharmacodynamic assessments of intravesical delivery systems, combination chemotherapy regimens, and targeted agents in a physiologically relevant context that subcutaneous models cannot approximate.

Cell Line Information: 5637

The table below presents comprehensive characterization data for the 5637 human bladder cancer cell line to guide experimental design and model selection.

Our Services

Alfa Cytology delivers a full-spectrum 5637 orthotopic mouse model service designed to advance your preclinical bladder cancer research, from meticulous cell line expansion and STR verification through surgical engraftment, in-life monitoring, and sophisticated endpoint histopathological and molecular analysis. Our team ensures reproducible tumor kinetics, rigorous quality standards, and adaptable study configurations to meet the unique demands of your therapeutic development program.

Workflow of 5637 Orthotopic Mouse Model Construction

Establishment of the 5637 orthotopic bladder cancer model follows a meticulously optimized surgical protocol that maximizes tumor engraftment while preserving animal welfare. The workflow integrates cell quality assurance, precision surgical technique, and longitudinal monitoring to yield consistent, publication-grade preclinical datasets.

1. Cell Line Authentication and Expansion: 5637 cells are verified by STR profiling and expanded in RPMI-1640 complete medium to ensure phenotypic stability and high viability prior to surgical preparation.
2. Host Selection and Acclimatization: Female immunodeficient mice—typically athymic nude or NOG/NSG strains—are selected to reduce procedural complexity and optimize engraftment; animals are acclimatized and health-screened before surgery.
3. Anesthesia and Preoperative Preparation: General anesthesia is induced and maintained with isoflurane or ketamine/xylazine; the lower abdomen is depilated and disinfected, and the bladder is manually emptied to facilitate wall visualization.
4. Surgical Exposure of the Bladder: A midline lower abdominal incision is made to exteriorize the bladder dome; curved forceps are used to gently stabilize the organ, enabling precise needle access without catheter interference.
5. Bladder Wall Cell Injection: A suspension of 2.5–5 × 10⁵ viable 5637 cells in PBS (with or without Matrigel) is slowly injected into the ventral bladder wall musculature using a fine-gauge needle under direct visualization, avoiding the trigone and ureteral orifices.
6. Surgical Closure and Postoperative Care: The bladder is returned to the peritoneal cavity, the abdominal wall and skin are closed with layered sutures, and mice are recovered on a heated pad with analgesic support per institutional guidelines.
7. Tumor Monitoring and Cohort Randomization: Tumor establishment is tracked weekly via MRI, ultrasonography, or bioluminescence imaging; upon reaching predetermined tumor burden thresholds, mice are randomized into vehicle and treatment arms.
8. Treatment Administration and In-Life Observations: Investigational agents are delivered according to protocol-defined schedules, with concurrent recording of body weight, clinical signs, and tumor dimensions to assess tolerability and preliminary efficacy.
9. Necropsy and Tissue Procurement: At study endpoint, bladders are excised en bloc with adjacent tissues; tumors are measured, photographed, and aliquoted for formalin-fixed paraffin embedding, snap-freezing, and downstream molecular analysis.
10. Histopathological and Molecular Analysis: Tumor sections undergo H&E staining, IHC for basal/luminal markers (CK5/14, EGFR, Ki-67, phospho-AKT), and optional RNA-seq or proteomic profiling to characterize pathway modulation and drug response.
11. Data Integration and Reporting: All imaging, biometric, and molecular data are compiled into a comprehensive study report with statistical analyses, tumor growth curves, and pharmacodynamic summaries suitable for regulatory or publication purposes.

Fig 2. 5637 Orthotopic Mouse Model construction workflow.

Case Study-5637 Orthotopic Mouse Model Development

In a recent preclinical program, the 5637 orthotopic bladder cancer model was established with reproducible tumor take and steady volumetric expansion over a multi-week treatment window. Dose-escalation cohorts receiving a DNA-damage response inhibitor demonstrated tumor growth delay relative to vehicle controls, accompanied by decreased phospho-CHK2 staining and elevated apoptotic index in post-treatment tumor sections. A parallel arm evaluating an EGFR-targeted agent showed modest monotherapy activity that was substantially enhanced when combined with a platinum-based backbone, suggesting synergy in the basal-subtype context. Full quantitative datasets—including tumor volume trajectories, survival metrics, body weight trends, and biomarker modulation—are available for review; please reach out to our scientific team to discuss how these findings can inform your specific compound development strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your 5637 orthotopic model program means gaining access to a technically refined service platform built around scientific precision and client-focused execution.

• Proven proficiency with basal-subtype bladder cancer models and optimized surgical protocols that yield consistent 5637 orthotopic engraftment and robust tumor kinetics.
• Integrated service architecture covering model generation, multimodal imaging, bioanalysis, and histopathology under one quality-managed roof.
• Flexible study architectures supporting monotherapy, combination, sequential, and biomarker-stratified designs aligned to your mechanism of action.
• Rigorous cell authentication, health surveillance, and documentation practices that uphold data integrity for regulatory and peer-review standards.
• Responsive project scientists who provide regular updates, troubleshoot technical issues proactively, and adapt timelines to your program milestones.
• Cost-efficient operations that compress preclinical timelines while maintaining the highest standards of animal welfare and scientific rigor.

Contact Us

To discuss how the 5637 orthotopic mouse model can strengthen your bladder cancer preclinical pipeline, we invite you to reach out to us for a confidential consultation. Our specialists will review your target profile, propose a tailored study design, and outline a clear path to generating the high-quality data your program demands. Contact us today and discover how Alfa Cytology can drive your next preclinical milestone forward.

For research use only. Not intended for any clinical use.